Sustainable synthesis of pharmaceuticals via heterogeneous photocatalytic [3+2] cycloaddition

27 June 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The Huisgen [3+2] cycloaddition reaction has long served as a cornerstone for synthesizing heterocyclic scaffolds in pharmaceutical chemistry. However, its reliance on halogenating oxidants, stoichiometric bases, and multistep protocols limits synthetic efficiency. Herein, we report a heterogeneous photocatalytic strategy that directly converts oximes and alkenes into isoxazolines and isoxazoles under mild, additive-free conditions. This one-step process leverages mesoporous graphitic carbon nitride (mpg-CN) as a recyclable photocatalyst and molecular oxygen as a benign terminal oxidant. The system demonstrates exceptional functional group tolerance, accommodating heterocycles, carbohydrates, and other sensitive motifs, while operating efficiently at mild condition. Scalability is achieved through continuous-flow implementation, enabling gram-scale synthesis of pharmacologically relevant heterocyclic cores. Combined mechanistic investigations and density functional theory (DFT) calculations demonstrate that the cascade reaction is primarily mediated through energy transfer processes. Its operational simplicity, environmental compatibility, and broad substrate scope position it as a transformative platform for academic and industrial applications.

Keywords

Heterogeneous Photocatalysis
Green Synthesis
Trifluoromethylisoxazoline Pharmaceuticals
Huisgen Cycloaddition
Additive-Free

Supplementary materials

Title
Description
Actions
Title
Supporting information
Description
All characterization data are included in the supplementary materials
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.